Ajanta Pharma, Sun Pharma, and Lupin are in focus as Ozempic Patent Expiry drives surge in pharma stocks ahead of launch, with companies gearing up for semaglutide generics in the fast-growing diabetes and weight-loss market.
Bharat Biotech is advancing vaccines to fight drug resistance, focusing on preventing hospital infections and reducing antibiotic use as antimicrobial resistance grows into a major global health threat.
Union Minister Jitendra Singh lays foundation for Rs 600 crore pharmaceutical facility in Kathua to boost India’s self-reliance in critical antibiotic manufacturing and reduce import dependence.
AstraZeneca Pharma India has received regulatory approval for Durvalumab for liver cancer treatment in India, marking a significant step in expanding cancer care options.
Zydus Lifesciences has partnered with Lupin to roll out its weight loss injection in India, expanding access to semaglutide in India for diabetes and obesity treatment as demand rises across the country.
.png "Ebglyss by Eli Lilly Shows Strong Results in Pediatric Dermatitis")
Eli Lilly and Company reports strong Phase 3 data for Ebglyss, showing major skin improvement and itch relief in children with moderate-to-severe atopic dermatitis.
Sun Pharma moves closer to expanding Ilumya’s use as the US FDA begins reviewing its application for psoriatic arthritis, backed by late-stage trial data showing promising results.
.png "Alkem Laboratories Gets Germany GMP Certificate for Baddi Plant")
Alkem Laboratories’ Baddi manufacturing facility in India receives Germany GMP certificate, validating compliance with international quality standards and boosting its global pharmaceutical presence.
.png "Lupin Targets US Growth With Complex Generics and Biosimilars")
Lupin is sharpening its US growth strategy by focusing on complex generics and biosimilars, aiming to tap higher-margin opportunities in the American pharmaceutical market as competition intensifies in traditional generics.
Piramal Pharma Solutions has completed its 1,500th ADC batch at its facility in Grangemouth, marking a key milestone in the company’s global ADC development and manufacturing journey.
.jpg)
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")